COST-EFFECTIVENESS OF A 13-VALENT CONJUGATE PNEUMOCOCCAL VACCINATION PROGRAM IN COPD PATIENTS AGED 50+ YEARS IN SPAIN
Author(s)
Rodríguez-GonzálezMoro JM1, Menendez R2, Campins M3, Lwoff N4, Oyagüez I5, Echave M5, Rejas J4, Antoñanzas F6
1Hospital Gregorio Marañon, Madrid, Spain, 2Hospital Universitario La Fe, Valencia, Spain, 3Hospital Vall d'Hebron, Barcelona, Spain, 4Pfizer SLU, Alcobendas, Spain, 5Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 6University of La Rioja, La Rioja, Spain
OBJECTIVES: Patients with chronic obstructive pulmonary disease (COPD) are at elevated risk of pneumococcal infection. A 13-valent-pneumococcal-conjugate vaccine (PCV13) was approved for adult protection against invasive disease and pneumonia caused by S
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PRS50
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Respiratory-Related Disorders